Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Tiny heart monitor could unlock secrets of deadly rhythms in amyloidosis

NCT ID NCT04856267

Knowledge-focused Sponsor: Marianna Fontana Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study looked at 110 people with cardiac amyloidosis, a condition where protein deposits build up in the heart. Researchers implanted a small device under the skin to continuously monitor heart rhythms for up to several years. The goal was to learn more about when and why dangerous abnormal heartbeats occur, which could help doctors decide when to use treatments like pacemakers. Participants may not have directly benefited, but the data could improve care for future patients.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
implantable loop recorder (LINQ device)
What this could lead to
If successful, this study could help doctors better predict and prevent dangerous heart rhythms in people with cardiac amyloidosis, potentially saving lives.
What could go wrong
This is an observational study, not a treatment trial. It may not directly benefit participants, and the findings might not change current care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

110 people

The number who actually took part.

Started

May 2021

Finished

Oct 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients attending the National Amyloidosis Centre

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age over 18 years * Diagnosed with cardiac AL amyloidosis or cardiac ATTR amyloidosis using standard diagnostic techniques and criteria at the NAC * Willing and able to provide written informed consent Exclusion Criteria: * Patient who already have a cardiac device inserted, such as a permanent pacemaker (PPM), implantable cardioverter-defibrillator (ICD) or implantable cardiac monitor (ILR) * Other pre-existing cardiac or other pathology which, in the investigators opinion, would adverse affect primary outcome data collection * Contraindication to CMR imaging

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Arrythmia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

AL amyloidosis Amyloid Neuropathies, Familial amyloidosis Arrhythmias, Cardiac cardiac rhythm disease Death, Sudden, Cardiac sudden arrhythmia death syndrome sudden cardiac arrest wild type ATTR amyloidosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Arrythmia Cardiac amyloidosis Sudden cardiac death

Contacts and locations

Locations

  • Royal Free London NHS Foundation Trust

    London, NW3 2QG, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.